Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 2021

View Archived Issues

Positive phase II data published from GENETIC-AF study of bucindolol in patients with heart failure

Syros enters clinical supply agreement with Roche to evaluate SY-5609 as part of INTRINSIC study

Enanta nominates EDP-235 as clinical candidate for the treatment of COVID-19

Suzhou Zelgen Biosciences discovers G12C mutant GTPase KRAS inhibitors

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent cereblon ligands

Hisun Accuray Therapeutics, Zhejiang Hisun Pharmaceutical present SHP-2 inhibitors

New thyroid hormone receptor agonists divulged by Eccogene

Aptahem reports positive preliminary results from GLP studies of Apta-1

Enrollment begins in phase II study of Stemedica's itMSCs in patients with COVID-19

Exicure provides updated interim data from phase Ib/II study of cavrotolimod

INPP5D inhibition reduces amyloid pathology in Alzheimer's disease model

First patient dosed in IMP-MEL study of PORT-2 for the treatment of melanoma and NSCLC

Clene provides topline data from REPAIR-PD and REPAIR-MS studies

MYMD-1 shows the ability to suppress cytokine storm in human cells

Nullifying necrosis: unfolded protein response inhibitors fight flesh-eating bacteria

Dosing begins in phase II portion of phase I/II trial of AKS-452

FDA places partial clinical hold on Aprea's myeloid malignancy programs

Enrollment starts in phase I study of ZYIL-1

Boehringer Ingelheim initiates phase I/II study of BI-765128 in diabetic macular ischemia

Labile iron pool radiotracer [18F]TRX can predict sensitivity to iron-targeted tumor therapies

GI Innovation begins patient enrollment in phase I/II study of GI-101

Enrollment ongoing in first-in-human study of [68Ga]-FF58

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...